Apatinib Combined With S-1 as Maintenance Therapy for HER-2 Negatived Gastric Cancer
Status:
Unknown status
Trial end date:
2020-07-01
Target enrollment:
Participant gender:
Summary
Apatinib is a novel drug which was produced by Jiangsu Hengrui Medicine Co.Ltd in China. It
is approved in advanced gastric cancer（GC）. The investigators just want to design such kind
of trail to prove its effect when combined with S-1 as maintenance in advanced HER-2
negatived GC treated with 4 cycles chemotherapy and valued as SD. Investigators will evaluate
progression free survival (PFS) and overall survival (OS).